Alternate Names for N OLLAS Epitope Tag Expression and Detection Kit
The pCMV-N-OLLAS vector provides a convenient vector to express recombinant proteins under control of the CMV promoter with an N-terminal OLLAS tag. Using the N-OLLAS vector the protein will be expressed in the cytoplasm. We recommend inserting your protein of interest into the vector in frame using the Hind III and Not I restriction sites shown above. Bacterial selection can be performed using Kanamycin, while Neomycin resistance can be used for screening mammalian transfectants. The OLLAS tag has been shown to be detectable at ~100-fold lower levels that similar commercially available tags using the OLLA-2 monoclonal antibody. The OLLAS tag has also been demonstrated to provide superior functionality whether used as an N-terminal, C-terminal, or internal tag on recombinant and fusion proteins without interfering with the biological activity of the tagged protein.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Kits are guaranteed for 6 months from date of receipt.
Publications for N OLLAS Epitope Tag Kit (NBK1-18296)(2)
We have publications tested in 5 applications: FLOW, ICC/IF, IHC-Fr, IP, WB.
Be the first to review our N OLLAS Epitope Tag Expression and Detection Kit and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.